Selected research
Industry Research
Non-Hodgkin's Lymphoma Drug Industry Research Report 2026
Market perspective
The global Non-Hodgkin's Lymphoma Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Non-Hodgkin's Lymphoma Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Non-Hodgkin's Lymphoma Drug market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Non-Hodgkin's Lymphoma Drug market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Non-Hodgkin's Lymphoma Drug include Acrotech Biopharma, Eagle Pharmaceuticals, Epizyme, Gilead Sciences, MundiPharma, Secura Bio, TG Therapeutics, Bayer and Roche, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Non-Hodgkin's Lymphoma Drug market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Non-Hodgkin's Lymphoma Drug.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Non-Hodgkin's Lymphoma Drug Market by Company
Acrotech Biopharma
Eagle Pharmaceuticals
Epizyme
Gilead Sciences
MundiPharma
Secura Bio
TG Therapeutics
Bayer
Roche
Teva
Eisai
Non-Hodgkin's Lymphoma Drug Segment by Type
Oral
Injection
Non-Hodgkin's Lymphoma Drug Segment by Application
Hospital
Retail Pharmacy
Other
Non-Hodgkin's Lymphoma Drug Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Non-Hodgkin's Lymphoma Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Non-Hodgkin's Lymphoma Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Non-Hodgkin's Lymphoma Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Non-Hodgkin's Lymphoma Drug companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Oral
- Injection
Applications
- Hospital
- Retail Pharmacy
- Other
Companies covered
- Acrotech Biopharma
- Eagle Pharmaceuticals
- Epizyme
- Gilead Sciences
- MundiPharma
- Secura Bio
- TG Therapeutics
- Bayer
- Roche
- Teva
- Eisai
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Non-Hodgkin's Lymphoma Drug by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Oral
- 2.2.3 Injection
- 2.3 Non-Hodgkin's Lymphoma Drug by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Hospital
- 2.3.3 Retail Pharmacy
- 2.3.4 Other
- 2.4 Assumptions and Limitations
3 Non-Hodgkin's Lymphoma Drug Breakdown Data by Type
- 3.1 Global Non-Hodgkin's Lymphoma Drug Historic Market Size by Type (2021-2026)
- 3.2 Global Non-Hodgkin's Lymphoma Drug Forecasted Market Size by Type (2027-2032)
4 Non-Hodgkin's Lymphoma Drug Breakdown Data by Application
- 4.1 Global Non-Hodgkin's Lymphoma Drug Historic Market Size by Application (2021-2026)
- 4.2 Global Non-Hodgkin's Lymphoma Drug Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Non-Hodgkin's Lymphoma Drug Market Perspective (2021-2032)
- 5.2 Global Non-Hodgkin's Lymphoma Drug Growth Trends by Region
- 5.2.1 Global Non-Hodgkin's Lymphoma Drug Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Non-Hodgkin's Lymphoma Drug Historic Market Size by Region (2021-2026)
- 5.2.3 Non-Hodgkin's Lymphoma Drug Forecasted Market Size by Region (2027-2032)
- 5.3 Non-Hodgkin's Lymphoma Drug Market Dynamics
- 5.3.1 Non-Hodgkin's Lymphoma Drug Industry Trends
- 5.3.2 Non-Hodgkin's Lymphoma Drug Market Drivers
- 5.3.3 Non-Hodgkin's Lymphoma Drug Market Challenges
- 5.3.4 Non-Hodgkin's Lymphoma Drug Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Non-Hodgkin's Lymphoma Drug Players by Revenue
- 6.1.1 Global Top Non-Hodgkin's Lymphoma Drug Players by Revenue (2021-2026)
- 6.1.2 Global Non-Hodgkin's Lymphoma Drug Revenue Market Share by Players (2021-2026)
- 6.2 Global Non-Hodgkin's Lymphoma Drug Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Non-Hodgkin's Lymphoma Drug Head Office and Area Served
- 6.4 Global Non-Hodgkin's Lymphoma Drug Players, Product Type & Application
- 6.5 Global Non-Hodgkin's Lymphoma Drug Manufacturers Established Date
- 6.6 Global Non-Hodgkin's Lymphoma Drug Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Non-Hodgkin's Lymphoma Drug Market Size (2021-2032)
- 7.2 North America Non-Hodgkin's Lymphoma Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Non-Hodgkin's Lymphoma Drug Market Size by Country (2021-2026)
- 7.4 North America Non-Hodgkin's Lymphoma Drug Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Non-Hodgkin's Lymphoma Drug Market Size (2021-2032)
- 8.2 Europe Non-Hodgkin's Lymphoma Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Non-Hodgkin's Lymphoma Drug Market Size by Country (2021-2026)
- 8.4 Europe Non-Hodgkin's Lymphoma Drug Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Non-Hodgkin's Lymphoma Drug Market Size (2021-2032)
- 9.2 Asia-Pacific Non-Hodgkin's Lymphoma Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Non-Hodgkin's Lymphoma Drug Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Non-Hodgkin's Lymphoma Drug Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Non-Hodgkin's Lymphoma Drug Market Size (2021-2032)
- 10.2 South America Non-Hodgkin's Lymphoma Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Non-Hodgkin's Lymphoma Drug Market Size by Country (2021-2026)
- 10.4 South America Non-Hodgkin's Lymphoma Drug Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Non-Hodgkin's Lymphoma Drug Market Size (2021-2032)
- 11.2 Middle East & Africa Non-Hodgkin's Lymphoma Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Non-Hodgkin's Lymphoma Drug Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Non-Hodgkin's Lymphoma Drug Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Acrotech Biopharma
- 12.1.1 Acrotech Biopharma Company Information
- 12.1.2 Acrotech Biopharma Business Overview
- 12.1.3 Acrotech Biopharma Revenue in Non-Hodgkin's Lymphoma Drug Business (2021-2026)
- 12.1.4 Acrotech Biopharma Non-Hodgkin's Lymphoma Drug Product Portfolio
- 12.1.5 Acrotech Biopharma Recent Developments
- 12.2 Eagle Pharmaceuticals
- 12.2.1 Eagle Pharmaceuticals Company Information
- 12.2.2 Eagle Pharmaceuticals Business Overview
- 12.2.3 Eagle Pharmaceuticals Revenue in Non-Hodgkin's Lymphoma Drug Business (2021-2026)
- 12.2.4 Eagle Pharmaceuticals Non-Hodgkin's Lymphoma Drug Product Portfolio
- 12.2.5 Eagle Pharmaceuticals Recent Developments
- 12.3 Epizyme
- 12.3.1 Epizyme Company Information
- 12.3.2 Epizyme Business Overview
- 12.3.3 Epizyme Revenue in Non-Hodgkin's Lymphoma Drug Business (2021-2026)
- 12.3.4 Epizyme Non-Hodgkin's Lymphoma Drug Product Portfolio
- 12.3.5 Epizyme Recent Developments
- 12.4 Gilead Sciences
- 12.4.1 Gilead Sciences Company Information
- 12.4.2 Gilead Sciences Business Overview
- 12.4.3 Gilead Sciences Revenue in Non-Hodgkin's Lymphoma Drug Business (2021-2026)
- 12.4.4 Gilead Sciences Non-Hodgkin's Lymphoma Drug Product Portfolio
- 12.4.5 Gilead Sciences Recent Developments
- 12.5 MundiPharma
- 12.5.1 MundiPharma Company Information
- 12.5.2 MundiPharma Business Overview
- 12.5.3 MundiPharma Revenue in Non-Hodgkin's Lymphoma Drug Business (2021-2026)
- 12.5.4 MundiPharma Non-Hodgkin's Lymphoma Drug Product Portfolio
- 12.5.5 MundiPharma Recent Developments
- 12.6 Secura Bio
- 12.6.1 Secura Bio Company Information
- 12.6.2 Secura Bio Business Overview
- 12.6.3 Secura Bio Revenue in Non-Hodgkin's Lymphoma Drug Business (2021-2026)
- 12.6.4 Secura Bio Non-Hodgkin's Lymphoma Drug Product Portfolio
- 12.6.5 Secura Bio Recent Developments
- 12.7 TG Therapeutics
- 12.7.1 TG Therapeutics Company Information
- 12.7.2 TG Therapeutics Business Overview
- 12.7.3 TG Therapeutics Revenue in Non-Hodgkin's Lymphoma Drug Business (2021-2026)
- 12.7.4 TG Therapeutics Non-Hodgkin's Lymphoma Drug Product Portfolio
- 12.7.5 TG Therapeutics Recent Developments
- 12.8 Bayer
- 12.8.1 Bayer Company Information
- 12.8.2 Bayer Business Overview
- 12.8.3 Bayer Revenue in Non-Hodgkin's Lymphoma Drug Business (2021-2026)
- 12.8.4 Bayer Non-Hodgkin's Lymphoma Drug Product Portfolio
- 12.8.5 Bayer Recent Developments
- 12.9 Roche
- 12.9.1 Roche Company Information
- 12.9.2 Roche Business Overview
- 12.9.3 Roche Revenue in Non-Hodgkin's Lymphoma Drug Business (2021-2026)
- 12.9.4 Roche Non-Hodgkin's Lymphoma Drug Product Portfolio
- 12.9.5 Roche Recent Developments
- 12.10 Teva
- 12.10.1 Teva Company Information
- 12.10.2 Teva Business Overview
- 12.10.3 Teva Revenue in Non-Hodgkin's Lymphoma Drug Business (2021-2026)
- 12.10.4 Teva Non-Hodgkin's Lymphoma Drug Product Portfolio
- 12.10.5 Teva Recent Developments
- 12.11 Eisai
- 12.11.1 Eisai Company Information
- 12.11.2 Eisai Business Overview
- 12.11.3 Eisai Revenue in Non-Hodgkin's Lymphoma Drug Business (2021-2026)
- 12.11.4 Eisai Non-Hodgkin's Lymphoma Drug Product Portfolio
- 12.11.5 Eisai Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst